Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Senti Biosciences, Inc. - Common Stock (NQ: SNTI ) 2.650 -0.060 (-2.21%) Streaming Delayed Price Updated: 3:53 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Senti Biosciences, Inc. - Common Stock < Previous 1 2 Next > Senti Bio Announces Reverse Stock Split July 16, 2024 Shares expected to begin trading on split-adjusted basis on July 18, 2024 From Senti Biosciences, Inc. Via GlobeNewswire Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks July 02, 2024 Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices. Via MarketBeat Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy July 01, 2024 $8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia May 13, 2024 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights May 09, 2024 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) April 30, 2024 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights March 21, 2024 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program January 05, 2024 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia December 22, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates November 13, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China November 06, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting October 31, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting September 27, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio to Participate in Upcoming Conferences September 26, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio to Participate in Upcoming Investor Conferences September 05, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates August 11, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners August 10, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting May 20, 2023 Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces First Quarter 2023 Results and Pipeline Updates May 09, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting May 02, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting April 17, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio to Participate in Upcoming Investor Conferences April 14, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation February 21, 2023 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Senti Biosciences Announces New Employment Inducement Grants February 03, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio to Present at the SVB Securities Global Biopharma Conference February 01, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance January 27, 2023 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference December 19, 2022 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event December 11, 2022 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting November 23, 2022 From Senti Biosciences, Inc. Via GlobeNewswire Senti Bio Reports Third Quarter Financial Results and Pipeline Updates November 10, 2022 From Senti Biosciences, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.